Incyte Corporation (INCY)
Incyte Stock Eyes Worst Day Since 2018 After Trial Results
Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective for half of participants.
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Incyte's skin disease drug meets main goal in two late-stage studies
Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.
Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.
Reevaluating Incyte Corporation After Earnings (Technical Analysis)
Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below its 30-week EMA, with short-term bearish momentum but long-term bullish momentum, making it a cautious buy. Volume analysis shows neutral institutional activity, and relative strength indicates INCY is trading on par with the S&P 500 since May 2024.
Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025
Incyte's Q4 2024 earnings showed mixed results with slight revenue beat but missed non-GAAP earnings estimates. The stock has declined due to 2025 guidance coming below expectations. Despite slowing sales growth for Jakafi and Opzelura, Incyte's pipeline with four product launches in 2025 and potential $1B incremental revenue by 2029 bodes well for continued growth. The company has a strong track record of revenue growth and a robust pipeline targeting over 10 high-impact product launches by 2030.
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.
Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY ) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Conference Call Participants Tazeen Ahmad - Bank of America David Lebowitz - Citibank Jessica Fye - JPMorgan Salveen Richter - Goldman Sachs James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Marc Frahm - TD Cowen Kelly Shi - Jefferies Brian Abrams - RBC Capital Markets Jay Olson - Oppenheimer Matt Phipps - William Blair Andrew Berens - Leerink Partners Andy Chen - Wolfe Research Salim Sayed - Mizuho Evan Seigerman - BMO Capital Markets Srikripa Devarakonda - Truist Securities Operator Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode.
Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Incyte (INCY) Q4 Earnings Miss Estimates
Incyte (INCY) came out with quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.06 per share a year ago.
